FDA to approve new Valeant drug application

Today, at stock market opening, Valeant Bausch & Lomb’s subsidiary announced that FDA approved a new drug application for loteprednol etabonate ophthalmic gel 0.38%, aimed at treating post-operative eye inflammation. Once obtained definitive approval, it is likely to be quickly placed on the market. Valeant’s shares immediately rose over 3% on the stock exchange.